Patient and disease characteristics
| . | < 4 (N = 57) . | ≥ 4 (N = 119) . | Total (N = 176) . | P value . |
|---|---|---|---|---|
| PEG doses | < .001 | |||
| N | 57 | 119 | 176 | |
| Median | 2.000 | 5.000 | 5.000 | |
| Range | 1.000 - 3.000 | 4.000 - 6.000 | 1.000 - 6.000 | |
| Extended induction status | .148 | |||
| Did not receive extended induction | 55 (96.5%) | 106 (89.1%) | 161 (91.5%) | |
| Received extended induction | 2 (3.5%) | 13 (10.9%) | 15 (8.5%) | |
| BMI (grouped) | .482 | |||
| Underweight | 1 (1.8%) | 2 (1.7%) | 3 (1.7%) | |
| Normal | 19 (33.3%) | 53 (44.5%) | 72 (40.9%) | |
| Overweight | 17 (29.8%) | 32 (26.9%) | 49 (27.8%) | |
| Obese | 20 (35.1%) | 32 (26.9%) | 52 (29.5%) | |
| Median BMI | 26.265 | 25.712 | 26.051 | .215 |
| Race | .164 | |||
| White | 52 (91.2%) | 85 (71.4%) | 137 (77.8%) | |
| Black | 2 (3.5%) | 11 (9.2%) | 13 (7.4%) | |
| Asian | 1 (1.8%) | 4 (3.4%) | 5 (2.8%) | |
| Native Hawaiian/Pacific Islander | 0 (0.0%) | 1 (0.8%) | 1 (0.6%) | |
| American Indian/Alaska native | 0 (0.0%) | 3 (2.5%) | 3 (1.7%) | |
| Unknown/not reported | 2 (3.5%) | 15 (12.6%) | 17 (9.7%) | |
| Ethnicity | ||||
| Hispanic | 6 (10.5%) | 20 (16.8%) | 26 (14.8%) | |
| Non-Hispanic | 44 (77.2%) | 81 (68.1%) | 125 (71.0%) | |
| Unknown/not reported | 7 (12.3%) | 18 (15.1%) | 25 (14.2%) | |
| CRLF-2 | .396 | |||
| N-tested cases | 31 | 59 | 90 | |
| No | 19 (73.1%) | 49 (81.7%) | 68 (79.1%) | |
| Yes | 7 (26.9%) | 11 (18.3%) | 18 (20.9%) | |
| Immunophenotype | .339 | |||
| B cell | 47 (82.5%) | 90 (75.6%) | 137 (77.8%) | |
| T cell | 10 (17.5%) | 29 (24.4%) | 39 (22.2%) | |
| Cytogenetics | .086 | |||
| N-missing | 35 | 51 | 86 | |
| Favorable | 0 (0.0%) | 8 (11.8%) | 8 (8.9%) | |
| Intermediate | 19 (86.4%) | 57 (83.8%) | 76 (84.4%) | |
| Unfavorable | 3 (13.6%) | 3 (4.4%) | 6 (6.7%) | |
| WBC | .335 | |||
| N-missing | 0 | 3 | 3 | |
| ≤30 | 47 (82.5%) | 87 (75.0%) | 134 (77.5%) | |
| >30 | 10 (17.5%) | 29 (25.0%) | 39 (22.5%) | |
| Ph-like | 1.000 | |||
| N-Tested cases | 31 | 59 | 90 | |
| No | 18 (69.2%) | 41 (68.3%) | 59 (68.6%) | |
| Yes | 8 (30.8%) | 19 (31.7%) | 27 (31.4%) | |
| Sex | .868 | |||
| Male | 37 (64.9%) | 75 (63.0%) | 112 (63.6%) | |
| Female | 20 (35.1%) | 44 (37.0%) | 64 (36.4%) | |
| Weight | .195 | |||
| Median | 82.000 | 77.000 | 78.500 | |
| Grouped age (y) | .097 | |||
| 15-19 | 8 (14.0%) | 36 (30.3%) | 44 (25.0%) | |
| 20-24 | 19 (33.3%) | 36 (30.3%) | 55 (31.2%) | |
| 25-29 | 13 (22.8%) | 27 (22.7%) | 40 (22.7%) | |
| 30-34 | 10 (17.5%) | 13 (10.9%) | 23 (13.1%) | |
| 35-39 | 7 (12.3%) | 7 (5.9%) | 14 (8.0%) | |
| Age (y) | .023 | |||
| Median | 26 | 23 | 24 | |
| Range | 18 - 39 | 17 - 38 | 17 - 39 | |
| Cause of death | .246 | |||
| N/A (Alive) | 40 (70.2%) | 97 (81.5%) | 137 (77.8%) | |
| Not related to protocol treatment or protocol disease | 4 (7.0%) | 3 (2.5%) | 7 (4.0%) | |
| Protocol disease-related | 12 (21.1%) | 18 (15.1%) | 30 (17.0%) | |
| Protocol treatment-related | 1 (1.8%) | 1 (0.8%) | 2 (1.1%) | |
| Risk group | 1.000 | |||
| High risk | 20 (35.1%) | 41 (34.5%) | 61 (34.7%) | |
| Standard risk | 37 (64.9%) | 78 (65.5%) | 115 (65.3%) |
| . | < 4 (N = 57) . | ≥ 4 (N = 119) . | Total (N = 176) . | P value . |
|---|---|---|---|---|
| PEG doses | < .001 | |||
| N | 57 | 119 | 176 | |
| Median | 2.000 | 5.000 | 5.000 | |
| Range | 1.000 - 3.000 | 4.000 - 6.000 | 1.000 - 6.000 | |
| Extended induction status | .148 | |||
| Did not receive extended induction | 55 (96.5%) | 106 (89.1%) | 161 (91.5%) | |
| Received extended induction | 2 (3.5%) | 13 (10.9%) | 15 (8.5%) | |
| BMI (grouped) | .482 | |||
| Underweight | 1 (1.8%) | 2 (1.7%) | 3 (1.7%) | |
| Normal | 19 (33.3%) | 53 (44.5%) | 72 (40.9%) | |
| Overweight | 17 (29.8%) | 32 (26.9%) | 49 (27.8%) | |
| Obese | 20 (35.1%) | 32 (26.9%) | 52 (29.5%) | |
| Median BMI | 26.265 | 25.712 | 26.051 | .215 |
| Race | .164 | |||
| White | 52 (91.2%) | 85 (71.4%) | 137 (77.8%) | |
| Black | 2 (3.5%) | 11 (9.2%) | 13 (7.4%) | |
| Asian | 1 (1.8%) | 4 (3.4%) | 5 (2.8%) | |
| Native Hawaiian/Pacific Islander | 0 (0.0%) | 1 (0.8%) | 1 (0.6%) | |
| American Indian/Alaska native | 0 (0.0%) | 3 (2.5%) | 3 (1.7%) | |
| Unknown/not reported | 2 (3.5%) | 15 (12.6%) | 17 (9.7%) | |
| Ethnicity | ||||
| Hispanic | 6 (10.5%) | 20 (16.8%) | 26 (14.8%) | |
| Non-Hispanic | 44 (77.2%) | 81 (68.1%) | 125 (71.0%) | |
| Unknown/not reported | 7 (12.3%) | 18 (15.1%) | 25 (14.2%) | |
| CRLF-2 | .396 | |||
| N-tested cases | 31 | 59 | 90 | |
| No | 19 (73.1%) | 49 (81.7%) | 68 (79.1%) | |
| Yes | 7 (26.9%) | 11 (18.3%) | 18 (20.9%) | |
| Immunophenotype | .339 | |||
| B cell | 47 (82.5%) | 90 (75.6%) | 137 (77.8%) | |
| T cell | 10 (17.5%) | 29 (24.4%) | 39 (22.2%) | |
| Cytogenetics | .086 | |||
| N-missing | 35 | 51 | 86 | |
| Favorable | 0 (0.0%) | 8 (11.8%) | 8 (8.9%) | |
| Intermediate | 19 (86.4%) | 57 (83.8%) | 76 (84.4%) | |
| Unfavorable | 3 (13.6%) | 3 (4.4%) | 6 (6.7%) | |
| WBC | .335 | |||
| N-missing | 0 | 3 | 3 | |
| ≤30 | 47 (82.5%) | 87 (75.0%) | 134 (77.5%) | |
| >30 | 10 (17.5%) | 29 (25.0%) | 39 (22.5%) | |
| Ph-like | 1.000 | |||
| N-Tested cases | 31 | 59 | 90 | |
| No | 18 (69.2%) | 41 (68.3%) | 59 (68.6%) | |
| Yes | 8 (30.8%) | 19 (31.7%) | 27 (31.4%) | |
| Sex | .868 | |||
| Male | 37 (64.9%) | 75 (63.0%) | 112 (63.6%) | |
| Female | 20 (35.1%) | 44 (37.0%) | 64 (36.4%) | |
| Weight | .195 | |||
| Median | 82.000 | 77.000 | 78.500 | |
| Grouped age (y) | .097 | |||
| 15-19 | 8 (14.0%) | 36 (30.3%) | 44 (25.0%) | |
| 20-24 | 19 (33.3%) | 36 (30.3%) | 55 (31.2%) | |
| 25-29 | 13 (22.8%) | 27 (22.7%) | 40 (22.7%) | |
| 30-34 | 10 (17.5%) | 13 (10.9%) | 23 (13.1%) | |
| 35-39 | 7 (12.3%) | 7 (5.9%) | 14 (8.0%) | |
| Age (y) | .023 | |||
| Median | 26 | 23 | 24 | |
| Range | 18 - 39 | 17 - 38 | 17 - 39 | |
| Cause of death | .246 | |||
| N/A (Alive) | 40 (70.2%) | 97 (81.5%) | 137 (77.8%) | |
| Not related to protocol treatment or protocol disease | 4 (7.0%) | 3 (2.5%) | 7 (4.0%) | |
| Protocol disease-related | 12 (21.1%) | 18 (15.1%) | 30 (17.0%) | |
| Protocol treatment-related | 1 (1.8%) | 1 (0.8%) | 2 (1.1%) | |
| Risk group | 1.000 | |||
| High risk | 20 (35.1%) | 41 (34.5%) | 61 (34.7%) | |
| Standard risk | 37 (64.9%) | 78 (65.5%) | 115 (65.3%) |